VJHemOnc is committed to improving our service to you

ASH 2019 | Genetic subtypes of AML that are more likely to respond to CPX-351

VJHemOnc is committed to improving our service to you

Jeffrey Lancet

Jeffrey Lancet, MD, Moffitt Cancer Center, Tampa, FL, discusses the analysis of genetic characteristics and outcomes by mutation status in the phase 3 study of CPX-351 (liposomal daunorubicin and cytarabine for injection) vs 7+3 chemotherapy in newly diagnosed high-risk or secondary acute myeloid leukemia (AML). TP53 mutations were associated with a poor prognosis, irrespective of treatment arm, whereas median overall survival was longer with CPX-351 compared with 7+3 among patients with two of the most common mutations, DNMT3A and TET2. This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.

Share this video  

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter